Exelixis and Ipsen Initiate Phase 3 Pivotal Trial (COSMIC-312) of Cabozantinib in Combination with Atezolizumab versus Sorafenib in Previously Untreated Advanced Hepatocellular Carcinoma – BioSpace

Spread the love

Exelixis and Ipsen Initiate Phase 3 Pivotal Trial (COSMIC-312) of Cabozantinib in Combination with Atezolizumab versus Sorafenib in Previously Untreated Advanced Hepatocellular Carcinoma BioSpace

Clinical trial will also explore single-agent activity of cabozantinib in the first-line setting –. ALAMEDA, Calif. & PARIS–(BUSINESS WIRE)– Exelixis, Inc.

…read more

Source:: Alameda, California News By Google News

Start a Conversation

[ghozylab-instagram feed=26796]